Several other anti-HER2 agents and an antibody–drug conjugate have been established as standard treatments for HER2-positive IBC-NSCLC in both the adjuvant and metastatic settings [83–91]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.